Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis
Koen Demyttenaere, Johan Detraux, Giorgio Racagni, et al.
CNS Drugs (2019) Vol. 33, Iss. 6, pp. 549-566
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Bipolar disorders
Roger S. McIntyre, Michael Berk, Elisa Brietzke, et al.
The Lancet (2020) Vol. 396, Iss. 10265, pp. 1841-1856
Closed Access | Times Cited: 678
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs
Rachel T.S. Chow, Daniel Whiting, Louis Favril, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 155, pp. 105454-105454
Open Access | Times Cited: 28
The Assessment and Treatment of Antipsychotic-Induced Akathisia
Tamara Pringsheim, David M. Gardner, Donald Addington, et al.
The Canadian Journal of Psychiatry (2018) Vol. 63, Iss. 11, pp. 719-729
Open Access | Times Cited: 68
Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
Tilahun Ali, Mekonnen Sisay, Mandaras Tariku, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0257129-e0257129
Open Access | Times Cited: 48
Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists
Michael Poyurovsky, Abraham Weizman
Drugs (2020) Vol. 80, Iss. 9, pp. 871-882
Closed Access | Times Cited: 40
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
Itaru Miura, Sho Horikoshi, Mizue Ichinose, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 3023-3031
Open Access | Times Cited: 13
Efficacy and Safety of Iloperidone in Bipolar Mania
Rosarelis Torres, Emily L. Czeisler, Sean R. Chadwick, et al.
The Journal of Clinical Psychiatry (2024) Vol. 85, Iss. 1
Open Access | Times Cited: 4
Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
Miquel Bernardo, Marina Dı́az-Marsá, Ana González‐Pinto, et al.
Neurology and Therapy (2025)
Open Access
An Evaluation of Iloperidone for Mania in Bipolar I Disorder
Kelen Caskey, Leigh Anne Nelson
Annals of Pharmacotherapy (2025)
Closed Access
Schizophrenia and Related Psychoses

(2025), pp. 1-278
Closed Access
The safety analysis of Lurasidone based on the real-world data of FAERS database
Ziyi Luo, Mengting Zhang, Weijian Liang, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, et al.
Schizophrenia Research (2021) Vol. 228, pp. 198-205
Open Access | Times Cited: 24
Druggable genome-wide Mendelian randomization for identifying the role of integrated stress response in therapeutic targets of bipolar disorder
Ting Zhai
Journal of Affective Disorders (2024) Vol. 362, pp. 843-852
Closed Access | Times Cited: 3
Treatable Hyperkinetic Movement Disorders Not to Be Missed
Aurélie Méneret, Béatrice Garcin, Solène Frismand, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 22
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 921-921
Open Access | Times Cited: 9
Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial
Jill Bjarke, Helga Nødland Gjerde, Hugo A. Jørgensen, et al.
Acta Neuropsychiatrica (2022) Vol. 34, Iss. 5, pp. 282-288
Open Access | Times Cited: 11
Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies
Georgios Schoretsanitis, Adriani Nikolakopoulou, Daniel Guinart, et al.
European Neuropsychopharmacology (2020) Vol. 35, pp. 1-11
Closed Access | Times Cited: 18
Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment
Shaina Musco, Vivian McAllister, Ian Caudle
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 18
Identification of clinical phenotypes in schizophrenia: the role of lurasidone
Marco Andrea Riva, Umberto Albert, Sergio De Filippis, et al.
Therapeutic Advances in Psychopharmacology (2021) Vol. 11
Open Access | Times Cited: 13
Brexpiprazole in the Treatment of Schizophrenia and Agitation in Alzheimer’s Disease
Lauren Stummer, Marija Marković, Megan Maroney
Neurodegenerative Disease Management (2020) Vol. 10, Iss. 4, pp. 205-217
Closed Access | Times Cited: 12
Review of Management Considerations for Excoriation Disorder in Older Adults
Michael Mandarino, Lauren Stummer, Ana F. Trueba, et al.
American Journal of Geriatric Psychiatry (2024)
Closed Access | Times Cited: 1
A review on side effect management of second generation antipsychotics to treat schizophrenia: a drug safety perspective
Wolfgang Strube, Elias Wagner, Jurjen J. Luykx, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 715-729
Closed Access | Times Cited: 1
Initiating Aripiprazole Lauroxil
Roger W. Sommi, Stephen R. Saklad, Peter J. Weiden, et al.
The Journal of Clinical Psychiatry (2024) Vol. 85, Iss. 3
Open Access | Times Cited: 1
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Eva-Maria Tsapakis, Michael Treiber, Calypso Mitkani, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5637-5637
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top